US 8609856
Crystalline forms of Febuxostat
granted A61PA61P19/06
Quick answer
US patent 8609856 (Crystalline forms of Febuxostat) held by Teva Pharmaceuticals USA, Inc. expires Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Teva Pharmaceuticals USA, Inc.
- Grant date
- Tue Dec 17 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 12 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61P, A61P19/06